Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 16/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17469784 | 0.85 | ATR (0.47) | ATRKITFLT3NTRK3 | |
| SCHEMBL17469791 | 0.78 | WDR5 (0.49) | F2PLGKITFLT3NTRK3 | |
| SCHEMBL18999195 | 0.76 | ATR (0.47) | ATR | |
| SCHEMBL17469787 | 0.70 | WDR5 (0.45) | F2PLGKITFLT3NTRK3 | |
| SCHEMBL17469786 | 0.70 | WDR5 (0.41) | F2PLGKITFLT3NTRK3 | |
| SCHEMBL17469737 | 0.70 | FLT3 (0.46) | ATRFLT3 | |
| SCHEMBL17469776 | 0.70 | NQO2 (0.56) | KITFLT3NTRK3 | |
| SCHEMBL19006228 | 0.67 | PLAU (0.40) | F2ATRHDAC1HDAC6 | |
| SCHEMBL17384053 | 0.65 | WDR5 (0.66) | F2HDAC6 | |
| Hydrochloric Acid SCHEMBL17377346 | 0.63 | WDR5 (0.63) | F2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190209548-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, BALTIMORE | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209548-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | MCL1, DPYD, TOP2B | F2 4544/4885PLG 4412/4885ATR 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.